Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study.
Insulin-like growth factor-1 (IGF1) is a potent mitogen. IGF-binding protein-3 (IGFBP3) binds and inhibits IGF1. High circulating IGF1 levels and low IGFBP3 levels are associated with increased risk of several cancers. We examined relationships between serum levels of these factors and hepatoma risk in a case-control study nested in a prospective cohort study (the Japan Collaborative Cohort Study (JACC Study)). A baseline survey was conducted from 1988 to 1990, and 39,242 subjects donated blood samples. Participants diagnosed with hepatoma by 1997 were considered cases for nested case-control studies. Ninety-one cases and 263 sex- and age-matched controls were analyzed. A conditional logistic model was used to estimate odds ratios (ORs) for the incidence of hepatoma associated with serum IGF1 and IGFBP3 levels. Neither IGF1 nor the molar ratio of IGF1/IGFBP3 was correlated with hepatoma risk. After adjustment for hepatitis viral infection, body mass index, smoking, and alcohol intake, a higher molar difference of (IGFBP3 - IGF1) was associated with a decreased hepatoma risk more than IGFBP3 alone (p for trend <0.001 and = 0.003, respectively). People in the highest quartile had a lower risk (OR = 0.098; 95 % confidence interval = 0.026-0.368). In subgroup analyses of males and females, the molar difference was associated with a decreased hepatoma risk (p for trend <0.05). In non-elderly individuals, the difference was inversely correlated with the incidence of hepatoma (p for trend <0.01). The molar difference of (IGFBP3 - IGF1) may be inversely associated with the incidence of hepatoma.
Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan. yadachi@sapmed.ac.jp.|Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan. yadachi@sapmed.ac.jp.
Yasushi
Y
Adachi
The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan.
Masanori
M
Nojima
Department of Public Health, School of Medicine, Sapporo Medical University, Sapporo, Japan.
Mitsuru
M
Mori
Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan.
Yasutaka
Y
Matsunaga
Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan.
Noriyuki
N
Akutsu
Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University, S-1, W-16, Chuo-ku, Sapporo, 060-8543, Japan.
Shigeru
S
Sasaki
Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Japan.
Takao
T
Endo
Division of Health Administration and Promotion, Faculty of Medicine, Tottori University, Yonago, Japan.
Youichi
Y
Kurozawa
Department of Preventive Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Kenji
K
Wakai
Department of Public Health, Hokkaido University School of Medicine, Sapporo, Japan.
Akiko
A
Tamakoshi
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D007564:Japan; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors
D014408:Biomarkers, Tumor; C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I
Hepatoma; IGF-binding protein (IGFBP); Insulin-like growth factor (IGF); Nested case-control study; Odds ratio
Cell. 1994 Dec 16;79(6):927-30
8001140
J Clin Invest. 1988 Apr;81(4):976-81
2832449
J Epidemiol. 2001 Jul;11(4):144-50
11512570
Cancer Sci. 2013 Jul;104(7):965-76
23879470
Turk J Gastroenterol. 2007 Dec;18(4):245-9
18080921
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7324-9
10377413
Clin Cancer Res. 2015 Feb 15;21(4):667-9
25303978
J Epidemiol. 2005 Mar;15 Suppl 1:S4-8
15881191
World J Gastroenterol. 2010 Dec 14;16(46):5779-89
21154998
World J Gastroenterol. 2006 Jul 7;12(25):3977-82
16810743
Asian Pac J Cancer Prev. 2009 Dec;10 Suppl:51-5
20553082
Science. 1998 Jan 23;279(5350):563-6
9438850
Cancer Sci. 2007 May;98(5):685-91
17359288
Cancer. 2002 Dec 15;95(12):2539-45
12467068
J Natl Cancer Inst. 1999 Apr 7;91(7):620-5
10203281
J Epidemiol. 2013;23(3):227-32
23583921
Br J Cancer. 2007 Aug 6;97(3):426-8
17637681
Oncol Rep. 2013 Sep;30(3):1337-45
23784592
J Pathol. 2005 Jan;205(2):145-53
15641016
Scand J Gastroenterol. 2000 Nov;35(11):1212-5
11145295
J Gastroenterol. 2010 Feb;45(2):159-70
19902140
Clin Cancer Res. 2011 Aug 1;17(15):5048-59
21642381
Clin Chim Acta. 2000 Apr;294(1-2):169-77
10727682
Lancet. 1998 May 9;351(9113):1393-6
9593409
Endocr Rev. 2002 Dec;23(6):824-54
12466191
Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2877-87
20810604
Clin Endocrinol (Oxf). 2003 Dec;59(6):699-706
14974910
Int J Cancer. 2004 Jul 1;110(4):584-8
15122592
J Epidemiol. 2005 Mar;15 Suppl 1:S67-73
15881197
Cancer Sci. 2013 Nov;104(11):1499-507
23889822
Oncol Lett. 2012 Mar;3(3):704-712
22740980
Br J Cancer. 2003 Mar 10;88(5):733-9
12618883
World J Gastroenterol. 2006 Jun 28;12(24):3821-8
16804965